• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
QRX
Click for more information
0.00% 2.8¢

QRXPHARMA LTD - Announcements

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
QRXMoxduo Post Advisory Committee Meeting Investor Call Details17/04/14
QRXTrading HaltPRICE SENSITIVE17/04/14
QRXFDA sets 22 April 2014 for Moxduo Advisory Committee Meeting24/03/14
QRXAppendix 3B - Exercise of Stock Options10/03/14
QRXASX / Media Release - Results Half Year 31 December 201325/02/14
QRXHalf Yearly Report and Accounts - 31 December 2013PRICE SENSITIVE25/02/14
QRXAppendix 3B - Exercise of Stock Options30/01/14
QRXAppendix 4C - Quarter Ended 31 December 2013PRICE SENSITIVE29/01/14
QRXDetails of Company Address22/01/14
QRXHoladay - Cease to be substantial holder17/12/13
QRXChange of Director's Interest Notice - Peter Campbell17/12/13
QRXQRxPharma Despatches SPP Holding Statements16/12/13
QRXAppendix 3B - Share Purchase Plan13/12/13
QRX$4.1 Million SPP Completes A$11.6 Million Capital RaisingPRICE SENSITIVE13/12/13
QRX25 May 2014 as New PDUFA Date for MOXDUO NDA11/12/13
QRXMOXDUO License with TEVA for Commercialisation in IsraelPRICE SENSITIVE27/11/13
QRXQRxPharma Refiles MOXDUO New Drug Application with the FDAPRICE SENSITIVE26/11/13
QRXChange in substantial holding19/11/13
QRXAppendix 3B - Option Issue19/11/13
QRXNotification Section 708A(5)(e) Corporations Act 2001 (Cth)18/11/13
QRXAppendix 3B - Placement Issue announced 13 November 201318/11/13
QRXShare Purchase Plan Opens 19 November 201315/11/13
QRXPlacement and SPP - ASX Listing Rule 3.10.3 Notice13/11/13
QRXResults of 2013 Annual General Meeting13/11/13
QRXChairman and Managing Director Addresses to Shareholders13/11/13
QRXSuccessful Completion of A$7.5 Million PlacementPRICE SENSITIVE13/11/13
QRXInvestor Update and Capital Raising - November 201311/11/13
QRXTrading HaltPRICE SENSITIVE11/11/13
QRXAppendix 4C - Quarter Ended 30 September 2013PRICE SENSITIVE28/10/13
QRXQRxPharma Extends MOXDUO License with AspenPRICE SENSITIVE15/10/13
QRXNotice of 2013 Annual General Meeting and Proxy Form10/10/13
QRXQRxPharma reports Positive Meeting with the FDA on MOXDUOPRICE SENSITIVE09/10/13
QRXAnnual Report to Shareholders - 201325/09/13
QRX2013 Annual General Meeting - Wednesday, 13 November 201317/09/13
QRXQRxPharma Announces MOXDUO License with AspenPRICE SENSITIVE11/09/13
QRXFDA Schedules Review Meeting Regarding MOXDUO NDA06/09/13
QRXASX/ Media Release - Preliminary Final Report 30 June 201329/08/13
QRXPreliminary Final Report - 30 June 2013PRICE SENSITIVE29/08/13
QRXCEO discusses Complete Response Letter on Open Briefing28/08/13
QRXComplete Response Letter from FDA regarding MOXDUO NDAPRICE SENSITIVE28/08/13
QRXTrading HaltPRICE SENSITIVE26/08/13
QRXAppendix 4C - Quarter Ended 30 June 2013PRICE SENSITIVE26/07/13
QRXQRxPharma Announces Collaboration with AesicaPRICE SENSITIVE22/07/13
QRXChange in substantial holding09/07/13
QRXCEO discusses MOXDUO NDA Review Update on Open Briefing27/06/13
QRXQRxPharma Updates MOXDUO NDA ReviewPRICE SENSITIVE26/06/13
QRXTrading HaltPRICE SENSITIVE26/06/13
QRXAppendix 3B - Exercise of Stock Options14/06/13
QRXQRxPharma Granted US Patent on Hybrid OpioidsPRICE SENSITIVE12/06/13
QRXAppendix 3B - Exercise of Stock Options05/06/13
QRXFDA sets 17 July 2013 for MOXDUO Advisory Committee MeetingPRICE SENSITIVE17/05/13
QRXAppendix 3B - Exercise of Stock Options09/05/13
QRXAppendix 4C - Quarter Ended 31 March 2013PRICE SENSITIVE29/04/13
QRXFDA sets 26 August 2013 as new PDUFA date for MOXDUO NDA14/03/13
QRXInvestor Presentation Update - March 201301/03/13
QRXQRxPharma Resubmits MOXDUO New Drug Application to the FDAPRICE SENSITIVE28/02/13
QRXAppendix 3B - Option Issue21/02/13
QRXInvestor Presentation Update - February 201318/02/13
QRXHalf Yearly Report and Accounts - 31 December 2012PRICE SENSITIVE18/02/13
QRXAppendix 4C - Quarter Ended 31 December 2012PRICE SENSITIVE24/01/13
QRXCEO discusses Path Forward for Resubmission of MOXDUO NDA17/01/13
QRXPath Forward For Resubmission of MOXDUO NDAPRICE SENSITIVE16/01/13
QRXAppendix 3B - Exercise of Stock Options14/01/13
QRXAppendix 3B - Exercise of Stock Options20/12/12
QRXInvestor Presentation Update - December 201211/12/12
QRXChange in substantial holding06/12/12
QRXMAP Cancellation06/12/12
QRXChange in substantial holding06/12/12
QRXCeasing to be a substantial holder28/11/12
QRXChange of Director's Interest Notice - Michael Quinn22/11/12
QRXChange of Director's Interest Notice - Gary Pace22/11/12
QRXChange of Director's Interest Notice - Peter Farrell22/11/12
QRXChange of Director's Interest Notice - Michael Quinn21/11/12
QRXChange of Director's Interest Notice - John Holaday12/11/12
QRXAppendix 3B - Option Issue12/11/12
QRXChange of Director's Interest Notice - Peter Campbell12/11/12
QRXChange of Director's Interest Notice - Peter Farrell12/11/12
QRXChange of Director's Interest Notice - Michael Quinn12/11/12
QRXChange of Director's Interest Notice - Gary Pace12/11/12
QRXResults of 2012 Annual General Meeting07/11/12
QRXChairman and Managing Director Addresses to Shareholders07/11/12
QRXAppendix 4C - Quarter Ended 30 September 2012PRICE SENSITIVE26/10/12
QRXStrategic Collaboration with Paladin LabsPRICE SENSITIVE10/10/12
QRXNotice of 2012 Annual General Meeting and Proxy Form05/10/12
QRXChange in substantial holding24/09/12
QRXAnnual Report to Shareholders - 201221/09/12
QRX2012 Annual General Meeting - Wednesday, 7 November 201213/09/12
QRXInvestor Presentation Update - September 201206/09/12
QRXIndependent Audit Report - 30 June 201203/09/12
QRXASX/ Media Release - Preliminary Final Report 30 June 201230/08/12
QRXPreliminary Final Report - 30 June 2012PRICE SENSITIVE30/08/12
QRXCEO discusses Productive Meeting with FDA regarding MOXDUO21/08/12
QRXProductive Meeting With FDA Regarding MOXDUO NDAPRICE SENSITIVE20/08/12
QRXAppendix 4C - Quarter Ended 30 June 2012PRICE SENSITIVE24/07/12
QRXChange in substantial holding11/07/12
PDL +Ceasing to be a substantial holder from BTT29/06/12
QRX +Ceasing to be a substantial holder from WBC29/06/12
QRXCEO discusses Complete Response Letter from FDA27/06/12
QRXComplete Response Letter from FDA regarding MOXDUO NDAPRICE SENSITIVE27/06/12
QRXTrading HaltPRICE SENSITIVE25/06/12
QRXMoxduo Post Advisory Committee Meeting Investor Call Details
17/04/14
QRXTrading Halt
17/04/14PRICE SENSITIVE
QRXFDA sets 22 April 2014 for Moxduo Advisory Committee Meeting
24/03/14
QRXAppendix 3B - Exercise of Stock Options
10/03/14
QRXASX / Media Release - Results Half Year 31 December 2013
25/02/14
QRXHalf Yearly Report and Accounts - 31 December 2013
25/02/14PRICE SENSITIVE
QRXAppendix 3B - Exercise of Stock Options
30/01/14
QRXAppendix 4C - Quarter Ended 31 December 2013
29/01/14PRICE SENSITIVE
QRXDetails of Company Address
22/01/14
QRXHoladay - Cease to be substantial holder
17/12/13
QRXChange of Director's Interest Notice - Peter Campbell
17/12/13
QRXQRxPharma Despatches SPP Holding Statements
16/12/13
QRXAppendix 3B - Share Purchase Plan
13/12/13
QRX$4.1 Million SPP Completes A$11.6 Million Capital Raising
13/12/13PRICE SENSITIVE
QRX25 May 2014 as New PDUFA Date for MOXDUO NDA
11/12/13
QRXMOXDUO License with TEVA for Commercialisation in Israel
27/11/13PRICE SENSITIVE
QRXQRxPharma Refiles MOXDUO New Drug Application with the FDA
26/11/13PRICE SENSITIVE
QRXChange in substantial holding
19/11/13
QRXAppendix 3B - Option Issue
19/11/13
QRXNotification Section 708A(5)(e) Corporations Act 2001 (Cth)
18/11/13
QRXAppendix 3B - Placement Issue announced 13 November 2013
18/11/13
QRXShare Purchase Plan Opens 19 November 2013
15/11/13
QRXPlacement and SPP - ASX Listing Rule 3.10.3 Notice
13/11/13
QRXResults of 2013 Annual General Meeting
13/11/13
QRXChairman and Managing Director Addresses to Shareholders
13/11/13
QRXSuccessful Completion of A$7.5 Million Placement
13/11/13PRICE SENSITIVE
QRXInvestor Update and Capital Raising - November 2013
11/11/13
QRXTrading Halt
11/11/13PRICE SENSITIVE
QRXAppendix 4C - Quarter Ended 30 September 2013
28/10/13PRICE SENSITIVE
QRXQRxPharma Extends MOXDUO License with Aspen
15/10/13PRICE SENSITIVE
QRXNotice of 2013 Annual General Meeting and Proxy Form
10/10/13
QRXQRxPharma reports Positive Meeting with the FDA on MOXDUO
09/10/13PRICE SENSITIVE
QRXAnnual Report to Shareholders - 2013
25/09/13
QRX2013 Annual General Meeting - Wednesday, 13 November 2013
17/09/13
QRXQRxPharma Announces MOXDUO License with Aspen
11/09/13PRICE SENSITIVE
QRXFDA Schedules Review Meeting Regarding MOXDUO NDA
06/09/13
QRXASX/ Media Release - Preliminary Final Report 30 June 2013
29/08/13
QRXPreliminary Final Report - 30 June 2013
29/08/13PRICE SENSITIVE
QRXCEO discusses Complete Response Letter on Open Briefing
28/08/13
QRXComplete Response Letter from FDA regarding MOXDUO NDA
28/08/13PRICE SENSITIVE
QRXTrading Halt
26/08/13PRICE SENSITIVE
QRXAppendix 4C - Quarter Ended 30 June 2013
26/07/13PRICE SENSITIVE
QRXQRxPharma Announces Collaboration with Aesica
22/07/13PRICE SENSITIVE
QRXChange in substantial holding
09/07/13
QRXCEO discusses MOXDUO NDA Review Update on Open Briefing
27/06/13
QRXQRxPharma Updates MOXDUO NDA Review
26/06/13PRICE SENSITIVE
QRXTrading Halt
26/06/13PRICE SENSITIVE
QRXAppendix 3B - Exercise of Stock Options
14/06/13
QRXQRxPharma Granted US Patent on Hybrid Opioids
12/06/13PRICE SENSITIVE
QRXAppendix 3B - Exercise of Stock Options
05/06/13
QRXFDA sets 17 July 2013 for MOXDUO Advisory Committee Meeting
17/05/13PRICE SENSITIVE
QRXAppendix 3B - Exercise of Stock Options
09/05/13
QRXAppendix 4C - Quarter Ended 31 March 2013
29/04/13PRICE SENSITIVE
QRXFDA sets 26 August 2013 as new PDUFA date for MOXDUO NDA
14/03/13
QRXInvestor Presentation Update - March 2013
01/03/13
QRXQRxPharma Resubmits MOXDUO New Drug Application to the FDA
28/02/13PRICE SENSITIVE
QRXAppendix 3B - Option Issue
21/02/13
QRXInvestor Presentation Update - February 2013
18/02/13
QRXHalf Yearly Report and Accounts - 31 December 2012
18/02/13PRICE SENSITIVE
QRXAppendix 4C - Quarter Ended 31 December 2012
24/01/13PRICE SENSITIVE
QRXCEO discusses Path Forward for Resubmission of MOXDUO NDA
17/01/13
QRXPath Forward For Resubmission of MOXDUO NDA
16/01/13PRICE SENSITIVE
QRXAppendix 3B - Exercise of Stock Options
14/01/13
QRXAppendix 3B - Exercise of Stock Options
20/12/12
QRXInvestor Presentation Update - December 2012
11/12/12
QRXChange in substantial holding
06/12/12
QRXMAP Cancellation
06/12/12
QRXChange in substantial holding
06/12/12
QRXCeasing to be a substantial holder
28/11/12
QRXChange of Director's Interest Notice - Michael Quinn
22/11/12
QRXChange of Director's Interest Notice - Gary Pace
22/11/12
QRXChange of Director's Interest Notice - Peter Farrell
22/11/12
QRXChange of Director's Interest Notice - Michael Quinn
21/11/12
QRXChange of Director's Interest Notice - John Holaday
12/11/12
QRXAppendix 3B - Option Issue
12/11/12
QRXChange of Director's Interest Notice - Peter Campbell
12/11/12
QRXChange of Director's Interest Notice - Peter Farrell
12/11/12
QRXChange of Director's Interest Notice - Michael Quinn
12/11/12
QRXChange of Director's Interest Notice - Gary Pace
12/11/12
QRXResults of 2012 Annual General Meeting
07/11/12
QRXChairman and Managing Director Addresses to Shareholders
07/11/12
QRXAppendix 4C - Quarter Ended 30 September 2012
26/10/12PRICE SENSITIVE
QRXStrategic Collaboration with Paladin Labs
10/10/12PRICE SENSITIVE
QRXNotice of 2012 Annual General Meeting and Proxy Form
05/10/12
QRXChange in substantial holding
24/09/12
QRXAnnual Report to Shareholders - 2012
21/09/12
QRX2012 Annual General Meeting - Wednesday, 7 November 2012
13/09/12
QRXInvestor Presentation Update - September 2012
06/09/12
QRXIndependent Audit Report - 30 June 2012
03/09/12
QRXASX/ Media Release - Preliminary Final Report 30 June 2012
30/08/12
QRXPreliminary Final Report - 30 June 2012
30/08/12PRICE SENSITIVE
QRXCEO discusses Productive Meeting with FDA regarding MOXDUO
21/08/12
QRXProductive Meeting With FDA Regarding MOXDUO NDA
20/08/12PRICE SENSITIVE
QRXAppendix 4C - Quarter Ended 30 June 2012
24/07/12PRICE SENSITIVE
QRXChange in substantial holding
11/07/12
PDL +Ceasing to be a substantial holder from BTT
29/06/12
QRX +Ceasing to be a substantial holder from WBC
29/06/12
QRXCEO discusses Complete Response Letter from FDA
27/06/12
QRXComplete Response Letter from FDA regarding MOXDUO NDA
27/06/12PRICE SENSITIVE
QRXTrading Halt
25/06/12PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 

Top Stories

MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up

Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
Australian Critical Mins jumps +13% on iron ore find at former lithium play Australian Critical Minerals (ASX:ACM) has seen its shares jump +13% to on an iron ore find in Western Australia’s Pilbara region.The iron ore find in question is based on rockchip samples gathered in a recent mapping and fieldwork run @ but the highest results sampled came in at ...
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025 Samples among the highest-ever-graded uranium soil samples recorded in mineral exploration history, and an imminent drill run.
This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game Today, one small pill holds the potential to transform cognitive medicine by addressing conditions like depression and Alzheimer’s. 
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.